Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab
In patients with uHCC treated with Ate/Bev, moderate elevation of liver enzymes (grade 2 irLI) was associated with significantly improved survival and tumor control.
Authors
- Jenhui Chen (ORCID: https://orcid.org/0000-0002-8372-9221)
- Po Ting Lin (ORCID: https://orcid.org/0000-0001-5907-7828)
- Eric Yi-Liang Shen (ORCID: https://orcid.org/0000-0003-2910-1393)
- Wei Teng (ORCID: https://orcid.org/0000-0001-5663-1440)
- Chun‐Yen Lin (ORCID: https://orcid.org/0000-0003-3007-3190)
- Chen‐Chun Lin
- Tai-Chi Wu
- Tsung‐Han Wu (ORCID: https://orcid.org/0000-0001-8455-8009)
- Chung‐Wei Su (ORCID: https://orcid.org/0000-0003-2778-3618)
- Shi‐Ming Lin (ORCID: https://orcid.org/0000-0001-7527-6181)
- Yi‐Chung Hsieh
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Taipei Tzu Chi Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-28
- DOI
- https://doi.org/10.3390/cancers17193157
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chang Gung Medical Foundation